We want to hear from you. Tell us what you think here or leave a comment on the app's iTunes or Google Play page. The updated ASCVD Risk Estimator Plus uses up-to-date ACC clinical policy and user ...

Cardiovascular medications frequently lead the polypharmacy category, often contributing to adverse clinical outcomes, and the most vulnerable among us are often prescribed the most complex regimens.

A unique blend of forum and network, the Cardiovascular (CV) Team Member Section and Leadership Council is advancing ACC's efforts to identify and address gaps in areas of professional importance to ...

With your help, ACC Advocacy actively works with Congress, state legislators, and other key decision makers to transform cardiovascular care and improve heart health. However, we need everyone's voice ...

Days alive out of health care and hospitalization (DAoH), a novel measure of outcomes in children undergoing cardiovascular surgery, offers advantages over the traditional outcome measure of days ...

Among patients with takotsubo syndrome (TTS), beta-blocker therapy was associated with lower follow-up mortality but not lower TTS recurrence, according to a study published Feb. 5 in JACC: Heart ...

Patients with a history of cardiovascular disease, compared with those without, had a higher incidence of sudden cardiac death (SCD), according to a study of 5.5 million Danish citizens in 2010, ...

In this episode, Drs. Joseph Marine and Rajeev Pathak dive into the ARREST-AF trial and its implications for ablation outcomes in atrial fibrillation (AFib) patients. Listen as they explore the key ...